The World Health Organisation (WHO) has officially listed the Alinity m MPXV assay for emergency use, marking a significant advancement in the global response to mpox outbreaks. This real-time PCR test, developed by Abbott Molecular Inc., will enhance diagnostic capabilities in regions facing rising cases of the monkeypox virus, particularly in Africa.
As of 2024, over 30,000 suspected mpox cases have been reported, with the Democratic Republic of the Congo, Burundi, and Nigeria experiencing the highest incidence. Alarmingly, only 37% of suspected cases in the Democratic Republic of the Congo have been tested this year, highlighting the urgent need for improved testing infrastructure.
The Alinity m MPXV assay allows for the rapid detection of monkeypox virus DNA from human skin lesion swabs, facilitating timely treatment and containment efforts. By increasing testing capacity, health authorities aim to mitigate the ongoing spread of the virus and ensure effective management of mpox cases.
Source: biospectrumindia.com, Date: 2024-10-04